---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-012507"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2023-01-23T23:59:59+00:00"
generated_at: "2026-06-20T11:38:21.057919+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Aadi Bioscience amends supply agreement with Fresenius Kabi for Fyarro; term extended to March 2024

## Summary
- Amendment extends contract term to March 31, 2024 (or later date if agreed).
- Pricing and minimum purchase quantity obligations for Fyarro were updated and revised.
- Agreement covers clinical and commercial manufacturing of Fyarro (sirolimus albumin-bound).
- Contains customary biotech manufacturing terms; full agreement to be filed later.

## SEC filing metadata
- accession: 0001193125-23-012507
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2023-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000119312523012507/0001193125-23-012507-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000119312523012507/d611917d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-012507
- JSON: https://secwatch.observer/filing/0001193125-23-012507.json
- Plain text: https://secwatch.observer/filing/0001193125-23-012507.txt

## Key facts
- Material Agreements
  Whitehawk Therapeutics, Inc. amended Amendment No.1 with Fresenius Kabi, LLC (effective 2023-01-17).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Fresenius Kabi, LLC
  - Effective: 2023-01-17
  source text: On January 17, 2023, Aadi Bioscience, Inc. (the “ Company ”) entered into Amendment No.1 (the “ Amendment ”) to the Negotiated Purchase Order Terms and Conditions for Clinical and Commercial Product (the “ Agreement ”) with Fresenius Kabi, LLC (“ Fresenius Kabi ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000119312523012507/0001193125-23-012507-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.